PM&R
Volume 2, Issue 6 , Pages 494-496 , June 2010

41st Walter J. Zeiter Lecture, 2009 PM&R in a Rapidly Changing World

References 

  1. Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet. 1974;II:1409–1412
  2. Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation of Duchenne muscular dystrophy (Interesting results in a trial of prednisone). Arch Neurol. 1987;44:812–817
  3. Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil. 2005;84:843–850
  4. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006;16:249–255
  5. Moxley RT, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005;64:13–20
  6. Hoffman E. Dystrophinopathies. Cambridge: Cambridge University Press; 2001;
  7. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9:177–189
  8. Andrews K, Kaplan LJ, Mercado S. Quality performance measures: the tie that binds reimbursement, licensure, certification and continuing medical education. PM R. 2009;1:740–743
  9. Rattray M. Valued-based physician reimbursement: challenges and opportunities for physical medicine and rehabilitation. PM R. 2009;1:706–708
  10. Greiner A, Knebel E. Health Professions Education: A Bridge to Quality. Washington, DC: National Academies Press; 2003;

PII: S1934-1482(10)00307-2

doi: 10.1016/j.pmrj.2010.04.002

PM&R
Volume 2, Issue 6 , Pages 494-496 , June 2010

Article Tools